SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition, Cumulative Effect (Details) - USD ($)		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2012
Balance Sheets [Abstract]
Contract assets			$ 10,000,000
Accounts receivable		$ 19,065,919	16,518,687
Deferred revenue		0	0
Deferred royalty buy-down		0	(200,000)	$ (400,000)	$ (1,500,000)
Deferred tax assets, net			313,768
Income tax payable		354,984	704,934
Retained earnings adjustment		96,646,527	72,176,719
Endo [Member]
Balance Sheets [Abstract]
Accounts receivable		$ 19,100,000	16,500,000	4,700,000
Deferred revenue				(6,400,000)
Deferred royalty buy-down				(2,500,000)
Accounts payable and accrued expenses -third party royalties				(400,000)
Deferred tax assets, net				1,700,000
Income tax payable				0
Retained earnings adjustment				(2,900,000)
ASU 2014-09 [Member] | Endo [Member]
Balance Sheets [Abstract]
Accounts receivable				12,300,000
Deferred revenue				(100,000)
Deferred royalty buy-down				(2,900,000)
Accounts payable and accrued expenses -third party royalties				(1,000,000)
Deferred tax assets, net				400,000
Income tax payable				(1,400,000)
Retained earnings adjustment				7,300,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Balance Sheets [Abstract]
Accounts receivable			9,700,000
Deferred tax assets, net			(1,100,000)
Income tax payable			1,900,000
Retained earnings adjustment			$ 11,200,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member] | Endo [Member]
Balance Sheets [Abstract]
Accounts receivable	[1]			7,600,000
Deferred revenue	[2]			6,300,000
Deferred royalty buy-down	[3]			(400,000)
Accounts payable and accrued expenses -third party royalties	[3]			(600,000)
Deferred tax assets, net	[4]			(1,300,000)
Income tax payable	[5]			(1,400,000)
Retained earnings adjustment				$ 10,200,000

[1] This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIAFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

[2] Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

[3] Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIAFLEX net sales reported to us by Endo for the fourth quarter of 2017.

[4] To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

[5] To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIAFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.